Last edition
News about "FY2023"
Pricing pressures and regulatory overhang affect margins of Indian pharma companies in FY2023: ICRA
Continued pricing pressures in the US and European markets and cost inflation likely to result in 50-100 bps contraction in operating profit margin for ICRA’s sample set in FY2023
<br />
FY2023 | 05/01/2023 | By Sudeep Soparkar | 625
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members